Research and Development

a. Pipeline

ⅰ. Development Pipeline

4 Development Pipeline

Indication and Feature   

1) DFP-10917
Indication
Relapsed/refractory acute myeloid leukemia
Feature   
Nucleoside analog delivered as a low-dose continuous infusion
2) DFP-14323
Indication
Lung cancer
Feature   
Low dose of Ubenimex (bestatin) with enhanced antitumor effect and improved immune function
3) DFP-11207
Indication
Solid tumors
Feature   
Improved 5-FU with antitumor activity but without thrombocytopenia
4) DFP-14927
Indication
Solid tumors
Feature   
Once weekly polymeric delivery of DFP-10917
5) DFP-10825
Indication
Peritoneal metastasis
Feature   
Nucleic acid drug designed to be effective with peritoneal administration
6) DFP-17729
Indication
Solid tumors
Feature   
Alkalizing agent that suppresses cancer cell growth

ⅱ. Status of Development Pipeline

the detail about 4 Development Pipeline

b. Licensing

ⅰ. Revenue Model

the detail about 4 Development Pipeline

ⅰ. Development Pipeline and Patent Protection

Status of patent acquisition of 4 Development Pipeline

ⅱ. Partnerships

ProductPartnerCountryContract RightsContract DateContract TypeContract Term
DFP-10917 Nippon Shinyaku, Co., Ltd. Japan Manufacturing and marketing March 24, 2017 Exclusive Upon Japan patent expiry or 15 years from first sales, whichever is later.
DFP-14323 Kyowa Chemical Industry Co., Ltd. Japan Manufacturing and marketing April 27, 2016 Exclusive Upon Japan patent expiry or 15 years from signing of contract, whichever is later.
DFP-17729 Nippon Chemiphar Co., Ltd. Japan Manufacturing and marketing March 26, 2020 Exclusive Upon termination of sales by Nippon Chemiphar or sub-licensee.

c. Presentations and Publications

DFP-10917

  • Conference
    American Society of Hematology 58th Annual Meeting & Exposition San Diego, CA /December 2016
    Title
    Phase I/II Study of DFP-10917 in Relapsed/Refractory AML Demonstrates Efficacy and Safety Profile Suitable for Phase III Study
    Presenter
    H. Kantarjian, E. Jabbour, G. Garcia-Manero, T. Kadia, C. Dinardo, N. Daver, G. Borthakur, N. Jain, J. Waukau, M. Kwari, F. Ravandi, B.Anderson, K. Iizuka, C. Jin, C. Zhang, W. Plunkett
  • Journal
    International of Oncology January 16, 2018
    Title
    Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo.
    Author
    Kenzo Iizuka, Chun Zhang, Kokoro Eshima, Cheng Jin, Kiyoshi Eshima, Masakazu Fukushima

DFP-10825

  • Journal
    INTERNATIONAL JOURNAL OF ONCOLOGY 38: 355-363, 2011
    Title
    Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
    Author
    KYUICHI KADOTA, CHENG-LONG HUANG, DAGE LIU, HIROYASU YOKOMISE, REIJI HABA and HIROMI WADA
  • Journal
    Molecular Pharmaceutics 2016, 13, 3955.3963
    Title
    Systemically Administered RNAi Molecule Sensitizes Malignant Pleural Mesotheliomal Cells to Pemetrexed Therapy
    Author
    Amr S. Abu Lila, Masakazu Fukushima, Cheng-Long Huang, Hiromi Wada, and Tatsuhiro Ishida
  • Journal
    Cancer Letters 400 (2017) 223-231
    Title
    Metronomic S-1 Dosing and thymidylate synthase silencing have synergistic antitumor efficacy in a colorectal cancer xenograft model
    Author
    Amr S. Abu Lila, Naoto Moriyoshi, Masakazu Fukushima, Cheng-Long Huang, Hiromi Wada and Tatsuhiro Ishida
  • Journal
    INTERNATIONAL JOURNAL OF ONCOLOGY 48: 1399-1407, 2016
    Title
    Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model
    Author
    AMR S ABU LILA, CHIHIRO KATO, MASAKAZU FUKUSHIMA, CHENG-LONG HUANG, HIROMI WADA and TATSUHIRO ISHIDA

DFP-17729

  • Journal
    ANTICANCER RESEARCH 40:873-880 (2020)
    Title
    Effects of Alkalization Therapy on Chemotherapy Outcomes in Metastatic or Recurrent Pancreatic Cancer
    Author
    REO HAMAGUCHI, RYOKO NARUI and HIROMI WADA